GlaxoSmithKline makes big down payment on biotech targeting 'synthetic viability' with startup funding, pipeline deals
Since joining British drugmaker GlaxoSmithKline in 2018, CSO Hal Barron has pushed to beef up the company’s oncology portfolio, taking a particular eye to “synthetic lethality” discovery work. Now, GSK is putting down a big chunk of change on the flip side of the coin — cell viability — for a range of potential therapies outside of cancer.
GSK will co-lead a Series A financing round with an undisclosed amount of cash for Adrestia Therapeutics, a biotech hoping to develop medicines targeting the “synthetic viability” of dysfunctional or dying cells in a range of therapeutic areas, GSK said Friday.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 124,200+ biopharma pros reading Endpoints daily — and it's free.